Azonan-(2Z)-ylideneamine | 116612-50-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 英文名称: Azonan-(2Z)-ylideneamine
• 英文别名: 3,4,5,6,7,8-hexahydro-2H-azonin-9-amine
• CAS: 116612-50-1
• 化学式: C₈H₁₆N₂
• mdl: MFCD19220064
• 分子量: 140.228
• InChiKey: NHHGJWDDKUEZBV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  38.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Azonan-(2Z)-ylideneamine 在 sodium butanolate 、 锌 作用下， 以 正丁醇 为溶剂， 反应 0.25h， 生成 12-amino-13-formamido-2,11,14-triazabicyclo<8.3.1>tetradeca-1(14),10,12-triene
  参考文献：
  名称：

  Ienaga, Kazuharu; Hasegawa, Taisuke; Brown, Desmond J., Journal of the Chemical Society. Perkin transactions I, 1988, p. 593 - 596

  摘要：

  DOI：
• 作为产物：
  描述：

  2-氮杂环壬酮 在 ammonium chloride 作用下， 以 乙醇 为溶剂， 反应 21.0h， 生成 Azonan-(2Z)-ylideneamine
  参考文献：
  名称：

  2-Iminopiperidine and Other 2-Iminoazaheterocycles as Potent Inhibitors of Human Nitric Oxide Synthase Isoforms

  摘要：

  A series of 2-iminoazaheterocycles. have been prepared and shown to be patent inhibitors of human nitric oxide synthase (NOS) isoforms. This series includes cyclic amidines ranging from five- to nine-membered rings, of which 2-iminopiperidine and 2-iminohomopiperidine were the most potent inhibitors, with IC50 values of 1.0 and 2.0 mu M, respectively, for human inducible nitric oxide synthase. This series of cyclic inhibitors was further expanded to include analogs with heteroatoms in the S-position of the six-membered ring. This modification was tolerated for sulfur and oxygen, but nitrogen reduced the inhibitory potency. The oral administration of 2-iminopiperidine in lipopolysaccharide (LPS)-treated rats inhibited the LPS-induced increase in plasma nitrite/nitrate levels in a dose-dependent manner, demonstrating its ability to inhibit inducible NOS activity in vivo. These cyclic amidines represent a new class of potent NOS inhibitors and the foundation for potential therapeutic agents.

  DOI：

  10.1021/jm950766n

文献信息

• Substituted Quinazoline or Pyridopyrimidine Derivative
  申请人：Mitsuya Morihiro

  公开号：US20080032996A1

  公开（公告）日：2008-02-07

  The present invention provides a compound having a glucokinase activating action being useful for prevention or treatment of diabetes mellitus, etc. being represented by the formula (I): X is nitrogen atom, etc.; Y is oxygen atom, etc.; R 1 is an optionally substituted five to six-membered heteroaryl group, etc.; R 2 is hydrogen atom or fluorine atom; and ring A is a monocyclic or bicyclic heteroaryl group which may have a substituent represented by the formula (II)] or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有激活葡萄糖激酶作用的化合物，该化合物可用于预防或治疗糖尿病等疾病，其表示式为(I)：其中，X为氮原子等；Y为氧原子等；R1为可选取代的五至六元杂环芳基基团等；R2为氢原子或氟原子；环A为单环或双环杂环芳基基团，其可具有由式(II)表示的取代基，或其药学上可接受的盐。
• IENAGA, KAZUHARU;HASEGAWA, TAISUKE;BROWN, DESMOND J.;PFLEIDERER, WOLFGANG, J. CHEM. SOC. PERKIN TRANS.,(1988) N 3, 539-595
  作者：IENAGA, KAZUHARU、HASEGAWA, TAISUKE、BROWN, DESMOND J.、PFLEIDERER, WOLFGANG

  DOI：——

  日期：——
• EP0789571A4
  申请人：——

  公开号：EP0789571A4

  公开（公告）日：1999-04-14
• CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE
  申请人：MERCK & CO., INC.

  公开号：EP0789571A1

  公开（公告）日：1997-08-20
• COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：PTC Therapeutics, Inc.

  公开号：EP2809322B9

  公开（公告）日：2019-10-30